The New England journal of medicine, 2022-02, Vol.386 (7), p.640-654
- Locke, Frederick L
- Miklos, David B
- Jacobson, Caron A
- Perales, Miguel-Angel
- Kersten, Marie-José
- Oluwole, Olalekan O
- Ghobadi, Armin
- Rapoport, Aaron P
- McGuirk, Joseph
- Pagel, John M
- Muñoz, Javier
- Farooq, Umar
- van Meerten, Tom
- Reagan, Patrick M
- Sureda, Anna
- Flinn, Ian W
- Vandenberghe, Peter
- Song, Kevin W
- Dickinson, Michael
- Minnema, Monique C
- Riedell, Peter A
- Leslie, Lori A
- Chaganti, Sridhar
- Yang, Yin
- Filosto, Simone
- Shah, Jina
- Schupp, Marco
- To, Christina
- Cheng, Paul
- Gordon, Leo I
- Westin, Jason R
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Locke, Frederick L
- Miklos, David B
- Jacobson, Caron A
- Perales, Miguel-Angel
- Kersten, Marie-José
- Oluwole, Olalekan O
- Ghobadi, Armin
- Rapoport, Aaron P
- McGuirk, Joseph
- Pagel, John M
- Muñoz, Javier
- Farooq, Umar
- van Meerten, Tom
- Reagan, Patrick M
- Sureda, Anna
- Flinn, Ian W
- Vandenberghe, Peter
- Song, Kevin W
- Dickinson, Michael
- Minnema, Monique C
- Riedell, Peter A
- Leslie, Lori A
- Chaganti, Sridhar
- Yang, Yin
- Filosto, Simone
- Shah, Jina
- Schupp, Marco
- To, Christina
- Cheng, Paul
- Gordon, Leo I
- Westin, Jason R
- Titel
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (7), p.640-654
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in patients with a response). High-grade toxic effects were common, but most patients recovered.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2116133Titel-ID: cdi_proquest_journals_2629416567
- Format
- –
- Schlagworte
- Adult, Age, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Autografts, B-cell lymphoma, Biological Products - adverse effects, Biological Products - therapeutic use, Bone marrow, Bone Marrow Transplantation, CD19 antigen, Cell therapy, Chemotherapy, Chimeric antigen receptors, Cytokines, Drug Resistance, Neoplasm, Female, Genetics, Genetics General, Hematology, Humans, Immunotherapy, Immunotherapy, Adoptive, Leukemia, Lymphocytes B, Lymphocytes T, Lymphoma, Lymphoma, Large B-Cell, Diffuse - drug therapy, Male, Medical prognosis, Middle Aged, Oncology, Progression-Free Survival, Receptors, Chimeric Antigen - antagonists & inhibitors, Statistical analysis, Stem Cell Transplantation, Transplantation, Autologous, Treatments in Oncology